Granulocyte colony-stimulating factors

Cancer Treatment and Research

Volumn 157, Issue , 2011, Pages 33-53

  Molineux, Graham ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLT3 LIGAND; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; JANUS KINASE 2; LORATADINE; MITOGEN ACTIVATED PROTEIN KINASE; OPIATE; PARACETAMOL; PLACEBO; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT STEM CELL FACTOR; STAT3 PROTEIN;

ACUTE GRAFT VERSUS HOST DISEASE; ANTIBODY TITER; ANTIGEN BINDING; BIOTINYLATION; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; BONE PAIN; CELL DIFFERENTIATION; CELL PROLIFERATION; CHRONIC GRAFT VERSUS HOST DISEASE; DISEASE SEVERITY; DISULFIDE BOND; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG USE; GENE DISRUPTION; GENETIC ANALYSIS; GENETIC VARIABILITY; GLYCOSYLATION; GRANULOCYTE; HOMOLOGOUS RECOMBINATION; HUMAN; LEUKOCYTOSIS; MAXIMUM PLASMA CONCENTRATION; MOLECULAR CLONING; NEUTROPENIA; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OSTEOBLAST; OSTEOLYSIS; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; REVIEW; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; STEM CELL MOBILIZATION; TISSUE DISTRIBUTION; TREATMENT INDICATION; X RAY CRYSTALLOGRAPHY;

ANIMALS; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIESIS; HUMANS;

EID: 78349232359     PISSN: 09273042     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-7073-2_3     Document Type: Review

References (120)

1. Hajdu SI. The discovery of blood cells. Ann Clin Lab Sci. 2003;33:237-8.
2. Pluznik DH, Sachs L. The cloning of normal "mast" cells in tissue culture. J Cell Physiol. 1965;66:319-24.
3. Bradley TR, Metcalf D. The growth of mouse bone marrow cells in vitro. Aust J Exp Biol Med Sci. 1966;44:287-99.
4. Stanley ER, Heard PM. Factors regulating macrophage production and growth purification and some properties of the colony stimulating factor from medium conditioned by mouse l neoplastic fibroblast cells. J Biol Chem. 1977;252:4305-12.
5. Burgess AW, Camakaris J, Purification MD. Properties of colony stimulating factor from mouse lung conditioned medium. J Biol Chem. 1977;252:1998-2003.
6. Gough NM, Gough J, Metcalf D, et al. Molecular cloning of cDNA encoding a murine haematopoietic growth regulator, granulocyte-macrophage colony stimulating factor. Nature. 1984;309:763-7.
7. Nicola NA, Metcalf D, Matsumoto M, Johnson GR. Purification of a factor inducing differentiation in murine myelomonocytic leukemia cells. Identification as granulocyte colony-stimulating factor. J Biol Chem. 1983;258:9017-23.
8. Metcalf D. Hematopoietic cytokines. Blood. 2008;111:485-91.
9. Souza LM, Boone TC, Gabrilove J, et al. Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science. 1986;232:61-5.
10. Welte K, Platzer E, Lu L, et al. Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor. Proc Natl Acad Sci USA. 1985;82:1526-30.
11. Nagata S, Tsuchiya M, Asano S, et al. Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor. Nature. 1986;319:415-18.
12. Zsebo KM, Cohen AM, Murdock DC, et al. Recombinant human granulocyte colony stimulating factor: molecular and biological characterization. Immunobiology. 1986;172:175-84.
13. Morstyn G, Campbell L, Souza LM, et al. Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet. 1988;1:667-72.
14. Gabrilove JL, Jakubowski A, Fain K, et al. Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium. J Clin Invest. 1988;82:1454-61.
15. Bronchud MH, Scarffe JH, Thatcher N, et al. Phase I/II study of recombinant human granu-locyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer. 1987;56:809-13.
16. Gabrilove JL, Jakubowski A, Scher H, et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med. 1988;318:1414-22.
17. Welte K, Gabrilove J, Bronchud MH, et al. Filgrastim (r-metHuG-CSF) - the first 10 years. Blood. 1996;88:1907-29.
18. Nicola NA, Biochemical MD. Properties of differentiation factors for murine myelo mono-cytic leukemic cells in organ conditioned media separation from colony stimulating factors. J Cell Physiol. 1981;109:253-64.
19. Cheers C, Haigh AM, Kelso A, et al. Production of colony-stimulating factors (CSFs) during infection: separate determinations of macrophage-, granulocyte-, granulocyte-macrophage-, and multi-CSFs. Infect Immun. 1988;56:247-51.
20. Tweardy DJ, Cannizzaro LA, Palumbo AP, et al. Molecular cloning and characterization of a complementary DNA for human granulocyte colony-stimulating factor (G-CSF) from a glioblastoma multiforme cell line and localization of the G-CSF gene to chromosome band 17q21. Cytogenet Cell Genet. 1987;46.
21. Ernst TJ, Ritchie AR, Demetri GD, Griffin JD. Regulation of granulocyte- and monocyte-colony stimulating factor mRNA levels in human blood monocytes is mediated primarily at a post-transcriptional level. J Biol Chem. 1989;264:5700-3.
22. Falkenburg JH, Harrington MA, de Paus RA, et al. Differential transcriptional and posttran-scriptional regulation of gene expression of the colony-stimulating factors by interleukin-1 and fetal bovine serum in murine fibroblasts. Blood. 1991;78:658-65.
23. Demetri GD, Griffin JD. Granulocyte colony-stimulating factor and its receptor. Blood. 1991;78:2791-808.
24. Miksits K, Beyer J, Siegert W. Serum concentrations of G-CSF during high-dose chemotherapy with autologous stem cell rescue. Bone Marrow Transplant. 1993;11:375-7.
25. Dunn SM, Coles LS, Lang RK, et al. Requirement for nuclear factor (NF)-kappa B p65 and NF-interleukin-6 binding elements in the tumor necrosis factor response region of the granulocyte colony-stimulating factor promoter. Blood. 1994;83:2469-79.
26. Ye P, Rodriguez FH, Kanaly S, et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med. 2001;194:519-27.
27. Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005;201:233-40.
28. Hill CP, Osslund TD, Eisenberg D. The structure of granulocyte-colony- stimulating factor and its relationship to other growth factors. Proc Natl Acad Sci USA. 1993;90: 5167-71.
29. Okabe M, Asano M, Kuga T, et al. In vitro and in vivo hematopoietic effect of mutant human granulocyte colony-stimulating factor. [see comments]. Blood. 1990;75:1788-93.
30. Lu HS, Clogston CL, Narhi LO, et al. Folding and oxidation of recombinant human granulocyte colony stimulating factor produced in Escherichia coli characterization of the disulfide-reduced intermediates and cysteine-serine analogs. J Biol Chem. 1992;267: 8770-7.
31. Kubota N, Orita T, Hattori K, et al. Structural characterization of natural and recombinant human granulocyte colony-stimulating factors. J Biochem. 1990;107:486-92.
32. Boulay J-L, O'Shea JJ, Paul WE. Molecular phylogeny within type 1 cytokines and their cognate receptors. Immunity. 2003;19:159-63.
33. Barge RM, De Koning JP, Pouwels K, et al. Tryptophan 650 of human granulocyte colony-stimulating factor (G-CSF) receptor, implicated in the activation of JAK2, is also required for G-CSF-mediated activation of signaling complexes of the p21ras route. Blood. 1996;87:2148-53.
34. Dong F, van Buitenen C, Pouwels K, et al. Distinct cytoplasmic regions of the human granulocyte colony-stimulating factor receptor involved in induction of proliferation and maturation. Mol Cell Biol. 1993;13:7774-81.
35. Fukunaga R, Ishizaka-Ikeda E, Nagata S. Growth and differentiation signals mediated by different regions in the cytoplasmic domain of granulocyte colony-stimulating factor receptor. Cell. 1993;74:1079-87.
36. Santini V, Scappini B, Indik ZK, et al. The carboxy-terminal region of the granulo-cyte colony-stimulating factor receptor transduces a phagocytic signal. Blood. 2003;101: 4615-22.
37. Dong F, Brynes RK, Tidow N, et al. Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia. N Engl J Med. 1995;333:487-93.
38. Dong F, Dale DC, Bonilla MA, et al. Mutations in the granulocyte colony-stimulating factor receptor gene in patients with severe congenital neutropenia. Leukemia. 1997;11:120-5.
39. Budel LM, Touw IP, Delwel R, Lowenberg B. Granulocyte colony-stimulating factor receptors in human acute myelocytic leukemia. Blood. 1989;74:2668-73.
40. Hanazono Y, Hosoi T, Kuwaki T, et al. Structural analysis of the receptors for granulocyte colony-stimulating factor on neutrophils. Exp Hematol. 1990;18:1097-103.
41. Khwaja A, Carver J, Jones HM, et al. Expression and dynamic modulation of the human granulocyte colony-stimulating factor receptor in immature and differentiated myeloid cells. Br J Haematol. 1993;85:254-9.
42. Shimoda K, Okamura S, Harada N, et al. Identification of a functional receptor for granulocyte colony-stimulating factor on platelets. J Clin Invest. 1993;91:1310-13.
43. Corcione A, Corrias MV, Daniele S, et al. Expression of granulocyte colony-stimulating factor and granulocyte colony-stimulating factor receptor genes in partially overlapping monoclonal B-cell populations from chronic lymphocytic leukemia patients. Blood. 1996;87:2861-9.
44. Matsushita K, Arima N. Involvement of granulocyte colony-stimulating factor in proliferation of adult T-cell leukemia cells. Leuk Lymphoma. 1998;31:295-304.
45. Boneberg EM, Hareng L, Gantner F, et al. Human monocytes express functional receptors for granulocyte colony-stimulating factor that mediate suppression of monokines and interferon-gamma. Blood. 2000;95:270-6.
46. Morikawa K, Morikawa S, Nakamura M, Miyawaki T. Characterization of granulocyte colony-stimulating factor receptor expressed on human lymphocytes. Br J Haematol. 2002;118:296-304.
47. Layton JE, Hall NE. The interaction of G-CSF with its receptor. Front Biosci. 2006;11: 3181-9.
48. Roberts AW. G-CSF: a key regulator of neutrophil production, but that's not all! Growth Factors. 2005;23:33-41.
49. Chang JM, Metcalf D, Gonda TJ, Johnson GR. Long-term exposure to retrovirally expressed granulocyte-colony-stimulating factor induces a nonneoplastic granulocytic and progenitor cell hyperplasia without tissue damage in mice. J Clin Invest. 1989;84:1488-96.
50. Yamada T, Kaneko H, Iizuka K, et al. Elevation of lymphocyte and hematopoietic stem cell numbers in mice transgenic for human granulocyte. Lab Invest. 1996;74:384-94.
51. Pojda Z, Molineux G, Dexter TM. Hemopoietic effects of short-term in vivo treatment of mice with various doses of rhG-CSF. Exp Hematol. 1990;18:27-31.
52. Cronkite EP, Bullis J, Pappas N, Shimosaka AS. In-vivo G-CSF induces anemia thrombope-nia and hemopoiesis in fatty marrow. Exp Hematol. 1990;18.
53. De Haan G, Engel C, Dontje B, et al. Mutual inhibition of murine erythropoiesis and granulopoiesis during combined erythropoietin, granulocyte colony-stimulating factor, and stem cell factor administration: in vivo interactions and dose-response surfaces. Blood. 1994;84:4157-63.
54. Lieschke GJ, Grail D, Hodgson G, et al. Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood. 1994;84:1737-46.
55. Coccia M, Hartley C, Sutherland W, et al. Neutropenia in a novel anti-mG-CSF autoantibody mouse model. Exp Hematol. 2000;28.
56. Lieschke GJ. CSF-deficient mice - what have they taught us? Ciba Found Symp. 1997;204:60-74.
57. Liu F, Wu HY, Wesselschmidt R, et al. Impaired production and increased apoptosis of neutrophils in granulocyte colony-stimulating factor receptor-deficient mice. Immunity. 1996;5:491-501.
58. Cebon J, Layton JE, Maher D, Morstyn G. Endogenous haemopoietic growth factors in neutropenia and infection. Br J Haematol. 1994;86:265-74.
59. Barth E, Fischer G, Schneider EM, et al. Peaks of endogenous G-CSF serum concentrations are followed by an increase in respiratory burst activity of granulocytes in patients with septic shock. Cytokine. 2002;17:275-84.
60. Lord BI. Myeloid cell kinetics in response to haemopoietic growth factors. Baillieres Clin Haematol. 1992;5:533-50.
61. Lord BI, Molineux G, Pojda Z, et al. Myeloid cell kinetics in mice treated with recombinant interleukin-3, granulocyte colony-stimulating factor (CSF), or granulocyte-macrophage CSF in vivo. Blood. 1991;77:2154-9.
62. Lord BI, Woolford LW, Molineux G. Kinetics of neutrophil production following filgrastim SD/01. Exp Hematol. 2000;28.
63. Takamatsu Y, Simmons PJ, Moore RJ, et al. Osteoclast-mediated bone resorption is stimulated during short-term administration of granulocyte colony-stimulating factor but is not responsible for hematopoietic progenitor cell mobilization. Blood. 1998;1.
64. Simon M, Lengfelder E, Reiter S, Hehlmann R. Osteoporosis in severe congenital neu-tropenia: inherent to the disease or a sequela of G-CSF treatment? Am J Hematol. 1996;52:127.
65. Dale DC, Cottle TE, Fier CJ, et al. Severe chronic neutropenia: treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry. Am J Hematol. 2003;72:82-93.
66. Takahashi T, Wada T, Mori M, et al. Overexpression of the granulocyte colony-stimulating factor gene leads to osteoporosis in mice. Lab Invest. 1996;74:827-34.
67. Froberg MK, Garg UC, Stroncek DF, et al. Changes in serum osteocalcin and bone-specific alkaline phosphatase are associated with bone pain in donors receiving granulocyte-colony-stimulating factor for peripheral blood stem and progenitor cell collection. Transfusion. 1999;39:410-14.
68. Semerad CL, Christopher MJ, Liu F, et al. G-CSF potently inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow. Blood. 2005;106:3020-7.
69. Lord BI, Molineux G, Chang J, et al. Hemopoietic cell kinetics in mice and humans during treatment in-vivo with hemopoietic growth factors. Exp Hematol. 1990;18.
70. Faust J, Lacey DL, Hunt P, et al. Osteoclast markers accumulate on cells developing from human peripheral blood mononuclear precursors. J Cell Biochem. 1999;72:67-80.
71. Gudi R, Krishnamurthy M, Pachter BR. Astemizole in the treatment of granulocyte colony-stimulating factor-induced bone pain. [see comment]. Ann Intern Med. 1995;123:236-7.
72. Morstyn G, Campbell L, Lieschke G, et al. Treatment of chemotherapy-induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy. J Clin Oncol. 1989;7:1554-62.
73. Di Leo A, Bajetta E, Nole F, et al. The intramuscular administration of granulocyte colony-stimulating factor as an adjunct to chemotherapy in pretreated ovarian cancer patients: an Italian Trials in Medical Oncology (ITMO) Group Pilot Study. Br J Cancer. 1994;69:961-6.
74. Bartocci A, Mastrogiannis DS, Migliorati G, et al. Macrophages specifically regulate the concentration of their own growth factor in the circulation. Proc Natl Acad Sci USA. 1987;84:6179-83.
75. Zink T, Ross A, Luers K, et al. Structure and dynamics of the human granulocyte colony-stimulating factor determined by NMR spectroscopy: loop mobility in a four-helix-bundle protein. Biochemistry. 1994;33:8453-63.
76. Ono M. Physicochemical and biochemical characteristics of glycosylated recombinant human granulocyte colony stimulating factor (lenograstim). Eur J Cancer. 1994;30A(Suppl-11).
77. Nissen C. Glycosylation of recombinant human granulocyte colony stimulating factor: implications for stability and potency. Eur J Cancer. 1994;30A(Suppl-4).
78. Pedrazzoli P, Gibelli N, Pavesi L, et al. Effects of glycosylated and non-glycosylated G-CSFs, alone and in combination with other cytokines, on the growth of human progenitor cells. Anticancer Res. 1996;16:1781-5.
79. Mire-Sluis AR, Das RG, Thorpe R. The international standard for granulocyte colony stimulating factor (G-CSF). Evaluation in an international collaborative study. Participants of the collaborative study. J Immunol Methods. 1995;179:117-26.
80. + cells. Haematologica. 1999;84:493-8.
81. Tanaka H, Tanaka Y, Shinagawa K, et al. Three types of recombinant human granulo-cyte colony-stimulating factor have equivalent biological activities in monkeys. Cytokine. 1997;9:360-9.
82. Bonig H, Silbermann S, Weller S, et al. Glycosylated vs non-glycosylated granulocyte colony-stimulating factor (G-CSF) - results of a prospective randomised monocentre study. Bone Marrow Transplant. 2001;28:259-64.
83. Uzumaki H, Okabe T, Sasaki N, et al. Identification and characterization of receptors for granulocyte colony-stimulating factor on human placenta and trophoblastic cells. Proc Natl Acad Sci USA. 1989;86:9323-6.
84. Piao YF, Okabe T. Receptor binding of human granulocyte colony-stimulating factor to the blast cells of myeloid leukemia. Cancer Res. 1990;50:1671-4.
85. Togawa A, Mizoguchi H, Toyama K, et al. Clinical evaluation of rhG-CSF in patients with neutropenia induced by chemotherapy for multiple myeloma. [Japanese]. Rinsho Ketsueki - Jpn J Clin Hematol. 2000;41:115-22.
86. Agency EM. Assessment report for Tevagrastim. 2008. http://www.emea. europa.eu/humandocs/PDFs/EPAR/tevagrastim/H-827-en6.pdf
87. Molineux G, Kinstler O, Briddell B, et al. A new form of filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol. 1999;27:1724-34.
88. Niven RW, Prestrelski SJ, Treuheit MJ, et al. Protein nebulization II. Stabilization of G-CSF to air-jet nebulization and the role of protectants. Int J Pharm (Amsterdam). 1996;127:191-201.
89. Watanabe Y, Kiriyama M, Oe J, et al. Pharmacodynamic activity (leukopoietic effect) of recombinant human granulocyte colony-stimulating factor (rhG-CSF) after rectal administration in rabbits with leukopenia induced by cyclophosphamide. Biol Pharm Bull. 1996;19:1064-7.
90. Jensen-Pippo KE, Whitcomb KL, Deprince RB, et al. Enternal bioavailability of human granulocyte colony stimulating factor conjugated with poly(ethylene glycol). Pharm Res (New York). 1996;13:102-7.
91. Tian SS, Lamb P, King AG, et al. A small, nonpeptidyl mimic of granulocyte-colony-stimulating factor [see comments]. Science. 1998;281:257-9.
92. Doyle ML, Tian S-S, Miller SG, et al. Selective binding and oligomerization of the murine granulocyte colony-stimulating factor receptor by a low molecular weight, nonpeptidyl ligand. J Biol Chem. 2003;278:9426-34.
93. Takatani H, Soda H, Fukuda M, et al. Levels of recombinant human granulocyte colony-stimulating factor in serum are inversely correlated with circulating neutrophil counts. Antimicrob Agents Chemother. 1996;40:988-91.
94. Furuya H, Wakayama T, Ohguni S, et al. Effect of continuous subcutaneous administration of a small dose of granulocyte colony stimulating factor (G-CSF) by the use of a portable infusion pump in patients with non-Hodgkin's lymphoma receiving chemotherapy. Int J Hematol. 1995;61:123-9.
95. Besarab A, Flaharty KK, Erslev AJ, et al. Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: the case for subcutaneous administration. J Am Soc Nephrol. 1992;2:1405-16.
96. Laterveer L, Lindley IJD, Hamilton MS, et al. Interleukin-8 induces rapid mobilization of hematopoietic stem cells with radioprotective capacity and long-term myelolymphoid repopulating ability. Blood. 1995;85:2269-75.
97. Liles WC, Broxmeyer HE, Rodger E, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood. 2003;102:2728-30.
98. Duhrsen U, Villeval JL, Boyd J, et al. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood. 1988;72:2074-81.
99. Lévesque J-P, Hendy J, Takamatsu Y, et al. Mobilization by either cyclophosphamide or granulocyte colony-stimulating factor transforms the bone marrow into a highly proteolytic environment. Exp Hematol. 2002;30:440-9.
100. Woll PJ, Thatcher N, Lomax L, et al. Use of hematopoietic progenitors in whole blood to support dose-dense chemotherapy: a randomized phase II trial in small-cell lung cancer patients. J Clin Oncol. 2001;19:712-19.
101. Klocke R, Kuhlmann MT, Scobioala S, et al. Granulocyte colony-stimulating factor (G-CSF) for cardio- and cerebrovascular regenerative applications. Curr Med Chem. 2008;15:968-77.
102. Vertesaljai M, Piroth Z, Fontos G, et al. Drugs, gene transfer, signaling factors: a bench to bedside approach to myocardial stem cell therapy. Heart Fail Rev. 2008;13:227-44.
103. Kurdi M, Booz GW. G-CSF-based stem cell therapy for the heart - unresolved issues. Part B: stem cells, engraftment, transdifferentiation, and bioengineering. Congest Heart Fail. 2007;13:347-51.
104. Kurdi M, Booz GWG-. CSF-based stem cell therapy for the heart-unresolved issues. Part A: paracrine actions, mobilization, and delivery. Congest Heart Fail. 2007;13:221-7.
105. Orlic D, Kajstura J, Chimenti S, et al. Bone marrow cells regenerate infarcted myocardium. [see comments]. Nature. 2001;410:701-5.
106. Okada H, Takemura G, Li Y, et al. Effect of a long-term treatment with a low-dose gran-ulocyte colony-stimulating factor on post-infarction process in the heart. J Cell Mol Med. 2008;12:1272-83.
107. Tatsumi K, Otani H, Sato D, et al. Granulocyte-colony stimulating factor increases donor mesenchymal stem cells in bone marrow and their mobilization into peripheral circulation but does not repair dystrophic heart after bone marrow transplantation. Circ J. 2008;72:1351-8.
108. + T cells in peripheral blood by recipient treatment with granulocyte colony-stimulating factor. Transplant Proc. 2008;40:1604-11.
109. Brunner S, Huber BC, Fischer R, et al. G-CSF treatment after myocardial infarction: impact on bone marrow-derived vs cardiac progenitor cells. Exp Hematol. 2008;36:695-702.
110. Zohlnhofer D, Ott I, Mehilli J, et al. Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial. [see comment]. JAMA. 2006;295:1003-10.
111. Ripa RS, Jorgensen E, Wang Y, et al. Stem cell mobilization induced by subcutaneous granulocyte-colony stimulating factor to improve cardiac regeneration after acute ST-elevation myocardial infarction: result of the double-blind, randomized, placebo-controlled stem cells in myocardial infarction (STEMMI) trial. [see comment]. Circulation. 2006;113:1983-92.
112. Erbs S, Linke A, Schachinger V, et al. Restoration of microvascular function in the infarct-related artery by intracoronary transplantation of bone marrow progenitor cells in patients with acute myocardial infarction: the Doppler Substudy of the Reinfusion of Enriched Progenitor Cells and Infarct Remodeling in Acute Myocardial Infarction (REPAIR-AMI) trial. [reprint in Nat Clin Pract Cardiovasc Med. 2008 Feb;5(2):78-9; PMID: 17984996].
113. Circulation. 2007;116:366-74.
114. Ince H, Petzsch M, Kleine HD, et al. Preservation from left ventricular remodeling by front-integrated revascularization and stem cell liberation in evolving acute myocar-dial infarction by use of granulocyte-colony-stimulating factor (FIRSTLINE-AMI). [see comment]. Circulation. 2005;112:3097-106.
115. Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist. 2007;12:713-18.
116. + myeloid cells. Nat Biotechnol. 2007;25:911-20.
117. Shojaei F, Wu X, Zhong C, et al. Bv8 regulates myeloid-cell-dependent tumour angiogene-sis. Nature. 2007;450:825-31.
118. Shojaei F, Wu X, Qu X, et al. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci USA. 2009;106:6742-7.
119. Movahedi K, Guilliams M, Van den Bossche J, et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood. 2008;111:4233-44.
120. Umemura N, Saio M, Suwa T, et al. Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics. J Leukoc Biol. 2008;83:1136-44.